BerGenBio

BerGenBio ASA - Correction, new share capital and warrants registered

Bergen 22 June 2023: Reference is made to the stock exchange announcement by

BerGenBio ASA (the "Company") on 14 June 2023 regarding the final results of the

partially underwritten rights issue of 2,500,000,000 new shares in the Company

(the "Offer Shares") at a subscription price of NOK 0.10 per new share, raising

gross proceeds of NOK 250 million (the "Rights Issue"). In addition, the

subscribers in the Rights Issue were allocated one warrant for every two Offer

Shares allocated to them and paid by them in the Rights Issue (the "Warrants").

The Rights Issue resulted in the issuance of 1,249,999,617 Warrants.

The Warrants and the share capital increase relating to the Rights Issue is now

registered with the Norwegian Register of Business Enterprises. After this, the

Company's new registered share capital is NOK 258,866,053.20 divided into

2,588,660,532 shares, each with a nominal value of NOK 0.10.

The Offer Shares and the Warrants are expected to be delivered to investors on

23 June 2023, however trading in the Offer Shares on Oslo Børs with ordinary T+2

settlement may accordingly commence now.

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

Rune Skeie, CFO, BerGenBio ASA

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate bemcentinib a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections.

BerGenBio is based in Bergen, Norway with a subsidiary in Oxford, UK. The

Company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more

information, visit www.bergenbio.com.

This information is published in accordance with the requirements of the Oslo

Rule Book II and is subject to the disclosure requirements pursuant to Section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal